Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

MORE THAN $3 MILLION IN GRANTS AWARDED TO CET LIFE SCIENCE CENTER TENANT COMPANIES

Cumberland Emerging Technologies
Posted on: 16 Oct 18
MORE THAN $3 MILLION IN GRANTS AWARDED TO CET LIFE SCIENCE CENTER TENANT COMPANIES

NASHVILLE, Tenn. (October 15, 2018) – Cumberland Emerging Technologies, Inc. (CET), an incubator of early-stage life science companies, today announced more than $3 million in research grant awards for three company tenants at the CET Life Sciences Center.

“This significant funding points to the important role the CET Life Science Center is playing in supporting the creation of innovative biomedical technologies that stimulate economic development in Tennessee,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals, Inc., one of CET’s founders.

The total of $3,070,000 in funding includes:

  • A $2 million grant from the U.S. National Cancer Institute (NCI) to support a joint research program involving Cumberland Pharmaceuticals Inc., Cumberland Emerging Technologies, Inc., and researchers at Vanderbilt University. The objective of the collaborative research program is to further develop a novel small molecule radiosensitizing agent for the treatment of certain lung cancers.  By enhancing the cancer’s sensitivity to radiation therapy, this technology addresses a significant medical need of improving clinical outcomes for these oncology patients. This Phase II grant is awarded under the Small Business Innovation Research (SBIR) funding mechanism and follows successful completion of an initial Phase I award.
  • A $750,000 grant to PATH EX, Inc from the National Science Foundation (NSF) to develop a fluidic platform for selective bacterial and endotoxin removal from blood. This technology can potentially serve as a novel blood cleansing therapeutic for diseases such as sepsis. This project by PATH EX proposes a novel approach to address the problem of sepsis through the direct removal of pathogens and associated toxins from circulation. Like the CET grant, this Phase II grant is awarded under the Small Business Innovation Research (SBIR) funding mechanism and follows successful completion of an initial Phase I award.
  • A $320,000 grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to fund research by IQuity in the use of its machine learning-based data mining and analytics platform – which analyzes many types of information, including genomic datasets, claims data and electronic medical records – to predict and detect Alzheimer’s disease. To date, IQuity has focused its research exclusively on autoimmune and related diseases, including multiple sclerosis, fibromyalgia syndrome and inflammatory bowel disease. The grant will allow the company to expand its focus to include Alzheimer’s disease and apply its genomic expertise to develop new diagnostic tools to help providers identify the disease early.

About Cumberland Emerging Technologies Inc.

Cumberland Emerging Technologies, Inc. (“CET”) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, Launch Tennessee, and China’s Gloria Pharmaceuticals. CET is working with a select group of academic research institutions located in the mid-south region of the U.S to develop therapeutic compounds addressing poorly met medical needs.  CET contributes product design and overall development support services to help university-based collaborators bridge the gap between discovery and the marketplace.

CET also operates the Nashville Life Sciences Center providing laboratory space, equipment, and infrastructure to support early-stage, life sciences companies.

For more information on CET see www.cet-fund.com

About PATH EX Inc.

PATH EX, Inc is a medical device startup company based in Nashville, TN. PATH EX is developing a unique pathogen extraction platform designed to directly capture and eradicate bacteria and associated toxins from the blood, regardless of bacterial type or drug-resistance. The PATH EX technology will allow for faster diagnosis of blood-borne infections by reducing the time required for bacteria culturing. Also, the PATH EX technology will enable the treatment of septic patients through direct and continuous removal of pathogens from circulation using a method similar to hemodialysis.

For more information on PATH EX see www.pathex.co

About IQuity

IQuity is a data analytics company leveraging machine learning to predict, detect, monitor, and stratify severity of disease for healthcare stakeholders, thereby improving patient outcomes and lowering costs. They bring value by automating the process of creating tailored models for disease management at scale, resulting in a collection of comprehensive customer insights and data science approaches to solve complex problems.

For more information, visit www.iquity.com and find IQuity on Facebook and Twitter at @iquityinc.

###

For more information:
www.cet-fund.com

Editor's Details

Damon Maida
the Bradford Group
damon@bradfordgroup.com

Last updated on: 16/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.